Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial

Background: Many patients with persistent asthma need both long-acting bron chodilators and inhaled corticosteroids for optimal asthma control. Objective: Our purpose was to compare the efficacy and safety of salmeterol 50 mu g combined with fluticasone 100 mu g (in a combination dry powder pr oduct) with that of placebo, fluticasone, or salmeterol alone. Methods: A 12-week randomized, double-blind, multicenter study was conducte d in 356 patients aged 12 years or older with asthma. After a 14-day screen ing period, patients were randomized to treatment with salmeterol 50 mu g c ombined with fluticasone 100 mu g (combination product), salmeterol 50 mu g , fluticasone 100 mu g, or placebo administered in the Diskus dry powder in haler (GlaxoWellcome, UK) twice daily. Results: Mean change in FEV1 at end point was significantly (P less than or equal to .003) greater with the combination product (0.51 L) compared with placebo (0.01 L), salmeterol (0.11 L), and fluticasone (0.28 L), The combi nation product significantly increased (P less than or equal to .013) area under the curve compared with placebo and fluticasone on day 1 and compared with placebo, salmeterol, and fluticasone at week 1 and week 12. Patients in the combination product group were less likely to withdraw from the stud y because of worsening asthma compared with those in the other groups (P le ss than or equal to .020). The combination product significantly increased (P less than or equal to .012) morning PEF (combination, 52.5 L/min; placeb o, -23.7 L/min; salmeterol, -1.7 L/min; fluticasone, 17.3 L/min) and evenin g PEF at end point compared with the other groups. The combination product significantly (P less than or equal to .025) reduced symptom scores and alb uterol use compared with the other treatments and increased the percentage of nights with no awakenings and the percentage of days with no symptoms co mpared with placebo and salmeterol. All treatments were equally well tolera ted. Conclusion: Salmeterol 50 mu g and fluticasone 100 mu g combined in the Dis kus powder delivery device offers significant clinical advantages over salm eterol or fluticasone alone at the same doses.